ATE396978T1 - Triazin-kinase-hemmer - Google Patents
Triazin-kinase-hemmerInfo
- Publication number
- ATE396978T1 ATE396978T1 AT00972036T AT00972036T ATE396978T1 AT E396978 T1 ATE396978 T1 AT E396978T1 AT 00972036 T AT00972036 T AT 00972036T AT 00972036 T AT00972036 T AT 00972036T AT E396978 T1 ATE396978 T1 AT E396978T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- methods
- compositions
- kinase inhibitors
- phosphoryl
- Prior art date
Links
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 abstract 3
- 208000024891 symptom Diseases 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 229940123468 Transferase inhibitor Drugs 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000003558 transferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15817699P | 1999-10-07 | 1999-10-07 | |
| US16697899P | 1999-11-23 | 1999-11-23 | |
| US17037899P | 1999-12-13 | 1999-12-13 | |
| US18326300P | 2000-02-17 | 2000-02-17 | |
| US21557600P | 2000-06-30 | 2000-06-30 | |
| US21980100P | 2000-07-20 | 2000-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE396978T1 true ATE396978T1 (de) | 2008-06-15 |
Family
ID=27558466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00972036T ATE396978T1 (de) | 1999-10-07 | 2000-10-06 | Triazin-kinase-hemmer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7074789B2 (de) |
| EP (1) | EP1218360B1 (de) |
| JP (1) | JP2003511378A (de) |
| AT (1) | ATE396978T1 (de) |
| AU (1) | AU770600B2 (de) |
| CA (1) | CA2386218A1 (de) |
| DE (1) | DE60039059D1 (de) |
| ES (1) | ES2306671T3 (de) |
| MX (1) | MXPA02003436A (de) |
| WO (1) | WO2001025220A1 (de) |
Families Citing this family (161)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1132387B1 (de) | 1998-11-17 | 2005-09-28 | Kumiai Chemical Industry Co., Ltd. | Pyrimidinylbenzimidazol- und triazinylbenzimidazol-derivate und agrikulte/hortikulte fungizide |
| AR029489A1 (es) * | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
| AU2001277621A1 (en) * | 2000-08-09 | 2002-03-04 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
| EP1698627A1 (de) | 2000-09-15 | 2006-09-06 | Vertex Pharmaceuticals Incorporated | Pyrazolverbindungen als Protein-Kinasehemmer |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| DK1318997T3 (da) | 2000-09-15 | 2006-09-25 | Vertex Pharma | Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer |
| US6716851B2 (en) | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| ATE430742T1 (de) * | 2000-12-21 | 2009-05-15 | Smithkline Beecham Corp | Pyrimidinamine als angiogenesemodulatoren |
| HUP0400639A3 (en) | 2000-12-21 | 2010-03-29 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them |
| US6864223B2 (en) * | 2000-12-27 | 2005-03-08 | Colgate-Palmolive Company | Thickened fabric conditioners |
| JP2005508841A (ja) * | 2001-03-29 | 2005-04-07 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
| US6864255B2 (en) | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
| US6881737B2 (en) | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
| AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| WO2003037346A1 (en) | 2001-10-31 | 2003-05-08 | Cell Therapeutics, Inc. | 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer |
| HUP0402657A3 (en) | 2001-11-28 | 2010-03-29 | Btg Int Ltd | Preventives or remedies for alzheimer' s disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds |
| DE10207037A1 (de) * | 2002-02-20 | 2003-08-28 | Bayer Cropscience Gmbh | 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| SE0200979D0 (sv) * | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| SE0302546D0 (sv) | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
| EP1515955A4 (de) * | 2002-06-17 | 2006-05-03 | Smithkline Beecham Corp | Chemisches verfahren |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| WO2004000820A2 (en) * | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| US7015227B2 (en) | 2002-06-21 | 2006-03-21 | Cgi Pharmaceuticals, Inc. | Certain amino-substituted monocycles as kinase modulators |
| SI2256108T1 (sl) * | 2002-07-18 | 2016-05-31 | Janssen Pharmaceutica N.V. | Substituirani triazinski kinazni inhibitorji |
| HRP20050082A2 (en) | 2002-07-19 | 2005-06-30 | Memory Pharmaceuticals Corporation | 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
| AU2003256616B2 (en) * | 2002-07-19 | 2009-08-27 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs |
| EP1542989B1 (de) | 2002-07-31 | 2007-04-18 | Critical Outcome Technologies, Inc. | Protein tyrosin kinase inhibitoren |
| DE60308387T2 (de) | 2002-08-02 | 2007-09-20 | Vertex Pharmaceuticals Inc., Cambridge | Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren |
| SE0202464D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Use of compounds |
| WO2004017950A2 (en) * | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| BR0314196A (pt) * | 2002-09-10 | 2005-07-26 | Scios Inc | Inibidores de tgf-beta |
| AU2003273675A1 (en) | 2002-10-09 | 2004-05-04 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
| US7419984B2 (en) | 2002-10-17 | 2008-09-02 | Cell Therapeutics, Inc. | Pyrimidines and uses thereof |
| JP2006516626A (ja) * | 2003-01-28 | 2006-07-06 | スミスクライン ビーチャム コーポレーション | 化学的化合物 |
| CL2004000303A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| GB0307268D0 (en) * | 2003-03-28 | 2003-05-07 | Syngenta Ltd | Organic compounds |
| US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| US6875781B2 (en) | 2003-04-04 | 2005-04-05 | Cell Therapeutics, Inc. | Pyridines and uses thereof |
| BR122019017579B8 (pt) | 2003-08-15 | 2021-07-27 | Novartis Ag | 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica |
| GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| JP2007507531A (ja) * | 2003-09-30 | 2007-03-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| WO2005033095A1 (en) * | 2003-10-03 | 2005-04-14 | Dow Agrosciences Llc | Fungicidal 4-(2-aminopyridin-4-yl)-n-phenyl-1,3,5-triazin-2-amine derivatives |
| EP1697384B1 (de) * | 2003-12-18 | 2008-04-02 | Janssen Pharmaceutica N.V. | Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel |
| US7572914B2 (en) * | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US7335770B2 (en) * | 2004-03-24 | 2008-02-26 | Reddy U5 Therapeutics, Inc. | Triazine compounds and their analogs, compositions, and methods |
| MXPA06012613A (es) | 2004-05-07 | 2007-01-31 | Amgen Inc | Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer. |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP1810677A1 (de) * | 2004-10-08 | 2007-07-25 | Takeda Pharmaceutical Company Limited | Rezeptor-funktionsregulierendes mittel |
| DE102004050196A1 (de) * | 2004-10-15 | 2006-04-20 | Sanofi-Aventis Deutschland Gmbh | Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| WO2006060172A2 (en) * | 2004-11-18 | 2006-06-08 | Irm Llc | Methods for identifying graft rejection suppressing compounds |
| NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
| JO3088B1 (ar) * | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
| EP1674467A1 (de) * | 2004-12-22 | 2006-06-28 | 4Sc Ag | 2,5- und 2,6-disubstituierte Benzazol-Derivate zur Verwendung als Protein Kinase Inhibitoren |
| RU2418788C2 (ru) * | 2005-03-10 | 2011-05-20 | Сги Фармасьютиклз, Инк. | Некоторые замещенные амиды, способ их получения и способ их применения |
| MX2007011041A (es) * | 2005-03-10 | 2008-02-22 | Cgi Pharmaceuticals Inc | Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas. |
| US20060211710A1 (en) * | 2005-03-17 | 2006-09-21 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| DE102005016634A1 (de) * | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
| US8778919B2 (en) * | 2005-06-30 | 2014-07-15 | Janssen Pharmaceutica Nv | Cyclic anilino—pyridinotriazines |
| NZ566021A (en) | 2005-07-26 | 2011-03-31 | Vertex Pharma | Benzimidazoles useful as inhibitors of protein kinases |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| TW200734327A (en) | 2005-11-03 | 2007-09-16 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
| MEP3808A (xx) | 2005-12-21 | 2010-02-10 | Novartis Ag | Derivati pirimidinil aril uree kao fgf inhibitori |
| EA018128B1 (ru) * | 2006-01-23 | 2013-05-30 | Амген Инк. | Модуляторы аурора киназы, способы их получения и их применение |
| CN101563336A (zh) * | 2006-03-16 | 2009-10-21 | 诺瓦提斯公司 | 用于治疗特别是黑素瘤的杂环有机化合物 |
| CN101437519A (zh) * | 2006-03-31 | 2009-05-20 | 艾博特公司 | 吲唑化合物 |
| EP2044084B1 (de) * | 2006-07-13 | 2016-02-17 | Janssen Pharmaceutica NV | Mtki-derivate des chinazolins |
| EP1882475A1 (de) * | 2006-07-26 | 2008-01-30 | Novartis AG | Methoden zur Behandlung von Erkrankungen, die durch den Fibroblastwachstumsfaktorrezeptor vermittelt werden |
| GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
| KR101364277B1 (ko) | 2006-12-08 | 2014-02-21 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 |
| AU2014200528B2 (en) * | 2006-12-15 | 2016-05-12 | Nantbio, Inc. | Triazine derivatives and their therapeutical applications |
| CA2672893C (en) | 2006-12-15 | 2016-02-23 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
| CN101663302B (zh) | 2007-04-18 | 2013-07-24 | 橘生药品工业株式会社 | 含氮稠环衍生物、包含所述含氮稠环衍生物的药物组合物及其医药用途 |
| DE102007024470A1 (de) | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren |
| TWI389893B (zh) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| US8415340B2 (en) * | 2007-07-25 | 2013-04-09 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
| US8318731B2 (en) | 2007-07-27 | 2012-11-27 | Janssen Pharmaceutica Nv | Pyrrolopyrimidines |
| BRPI0812594A2 (pt) * | 2007-08-10 | 2015-06-23 | Lundbeck & Co As H | Composto ou sal ou hidrato do mesmo, composição farmacêutica, métodos para modulação da atividade de um receptor p2x7, para tratamento de uma condição responsiva á modulação do receptor p2x7 em um paciente, para inibição de morte de células gangliônicas retinais em um paciente, para determinação da presença ou ausência de receptor p2x7 em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal ou hidrato do mesmo. |
| US20090062320A1 (en) * | 2007-08-28 | 2009-03-05 | Vito Guagnano | Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor |
| MX2010005033A (es) | 2007-11-06 | 2010-05-27 | Du Pont | Aminas heterociclicas fungicidas. |
| EP2072502A1 (de) | 2007-12-20 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren |
| EP2225226B1 (de) | 2007-12-26 | 2016-08-17 | Critical Outcome Technologies, Inc. | Verbindungen und ihre verwending in einem verfahren zur behandlung von krebs |
| US20110092452A1 (en) * | 2008-03-05 | 2011-04-21 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
| DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| MX2010012703A (es) | 2008-05-21 | 2010-12-21 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| EP3023426A1 (de) | 2008-07-17 | 2016-05-25 | Critical Outcome Technologies, Inc. | Thiosemicarbazonhemmerverbindungen und krebsbehandlungsverfahren |
| CN102239160A (zh) * | 2008-11-13 | 2011-11-09 | 拜尔农科股份公司 | 作为杀真菌剂的取代的(吡啶基)-嗪基胺衍生物 |
| BRPI0914399A2 (pt) * | 2008-11-13 | 2015-08-04 | Bayer Cropscience Ag | "composto de fórmula (i), composto de fórmula (ii), composição fungicida, método para o controle do fungo fitopatogênico de culturas e método para o combate de fungos fitopatogênicos e produtores de micotoxinas" |
| WO2010096314A1 (en) * | 2009-02-18 | 2010-08-26 | Amgen Inc. | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS |
| EP2221053A1 (de) * | 2009-02-20 | 2010-08-25 | Albert-Ludwigs-Universität Freiburg | Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen |
| JP2012528177A (ja) * | 2009-05-27 | 2012-11-12 | アボット・ラボラトリーズ | キナーゼ活性のピリミジン阻害剤 |
| EP2440050A4 (de) * | 2009-06-08 | 2013-04-03 | California Capital Equity Llc | Triazinderivate und ihre therapeutische anwendung |
| US20130023497A1 (en) * | 2009-06-08 | 2013-01-24 | Chunlin Tao | Triazine Derivatives and their Therapeutical Applications |
| CN102573473B (zh) | 2009-06-09 | 2015-05-27 | 加利福尼亚资本权益有限责任公司 | 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物 |
| JP2012529517A (ja) * | 2009-06-09 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | ベンジル置換トリアジン誘導体類及びそれらの治療応用 |
| KR20120026611A (ko) * | 2009-06-09 | 2012-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 헷지호그 신호전달의 피리딜-트리아진 억제제 |
| MA33501B1 (fr) | 2009-07-02 | 2012-08-01 | Sanofi Sa | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| IN2012DN03180A (de) * | 2009-10-30 | 2015-09-25 | Novartis Ag | |
| US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| CN102933561B (zh) * | 2010-03-22 | 2016-05-11 | 利德发现中心有限责任公司 | 具有药学活性的二取代三嗪衍生物 |
| US8987272B2 (en) | 2010-04-01 | 2015-03-24 | Critical Outcome Technologies Inc. | Compounds and method for treatment of HIV |
| KR20130108543A (ko) | 2010-08-05 | 2013-10-04 | 암젠 인코포레이션 | 역형성 림프종 키나제를 억제하는 벤즈이미다졸 및 아자벤즈이미다졸 화합물 |
| DK2655361T3 (en) | 2010-12-21 | 2016-05-23 | Bayer Ip Gmbh | PROCEDURE FOR PREPARING TRIAZINYL-SUBSTITUTED OXINDOLS |
| JP2012153674A (ja) * | 2011-01-28 | 2012-08-16 | Astellas Pharma Inc | ジ（アリールアミノ）アリール化合物の製造方法及びその合成中間体 |
| WO2012117048A1 (en) | 2011-03-02 | 2012-09-07 | Lead Discovery Center Gmbh | Pharmaceutically active disubstituted triazine derivatives |
| JP5947818B2 (ja) | 2011-03-02 | 2016-07-06 | リード ディスカバリー センター ゲーエムベーハー | 薬学的活性化二置換ピリジン誘導体 |
| CA2833288A1 (en) | 2011-04-19 | 2012-10-26 | Bayer Intellectual Property Gmbh | Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines |
| TWI555737B (zh) | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| EP2527332A1 (de) | 2011-05-24 | 2012-11-28 | Bayer Intellectual Property GmbH | 4-Aryl-N-Phenyl-1,3,5-Triazin-2-Amine mit einer Sulfoximingruppe als CDK9-Hemmer |
| CN102285969B (zh) * | 2011-06-28 | 2013-06-19 | 山东大学 | N-1-取代哌啶-4-芳胺类衍生物及其制备方法与应用 |
| JP5976814B2 (ja) | 2011-09-16 | 2016-08-24 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | スルホキシイミン基を含有する二置換５−フルオロピリミジン誘導体 |
| EP2755956B1 (de) | 2011-09-16 | 2016-05-18 | Bayer Intellectual Property GmbH | 2,4-disubstituierte 5-fluor-pyrimidine als selektive cdk9 inhibitoren |
| WO2013047411A1 (ja) * | 2011-09-29 | 2013-04-04 | 富士フイルム株式会社 | 新規なトリアジン誘導体、紫外線吸収剤 |
| IN2014KN02601A (de) | 2012-04-24 | 2015-05-08 | Vertex Pharma | |
| CA2888381A1 (en) | 2012-10-18 | 2014-04-24 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group |
| ES2595222T3 (es) | 2012-10-18 | 2016-12-28 | Bayer Pharma Aktiengesellschaft | Derivados de 5-fluoro-N-(piridin-2-il)piridin-2-amina que contienen un grupo sulfona |
| TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物 |
| EA035349B1 (ru) | 2012-11-21 | 2020-05-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1 |
| SMT202100687T1 (it) | 2013-03-12 | 2022-01-10 | Vertex Pharma | Inibitori della dna-pk |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| EP2988744A4 (de) * | 2013-04-26 | 2016-11-02 | Merck Sharp & Dohme | Thiazolsubstituierte aminoheteroaryle als milztyrosinkinasehemmer |
| GB2516303A (en) * | 2013-07-18 | 2015-01-21 | Redx Pharma Ltd | Compounds |
| WO2015030847A1 (en) | 2013-08-30 | 2015-03-05 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| PT3409674T (pt) | 2013-10-17 | 2022-07-18 | Blueprint Medicines Corp | Processo para preparar composições úteis para tratar distúrbios relacionados com kit |
| WO2015076801A1 (en) * | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted triazine bmi-1 inhibitors |
| EP3119762B9 (de) * | 2014-03-20 | 2021-10-20 | Capella Therapeutics, Inc. | Benzimidazolderivate als erbb-tyrosinkinasehemmer zur behandlung von krebs |
| BR112017000714A2 (pt) * | 2014-07-16 | 2018-01-09 | Novogen ltd | indols funcionalizados e substituídos como agentes anti-câncer |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| EP3207037B1 (de) | 2014-10-16 | 2019-01-23 | Bayer Pharma Aktiengesellschaft | Fluorierte benzofuranylpyrimidinderivate mit einer sulfongruppe |
| WO2016150893A1 (en) | 2015-03-24 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma |
| WO2016150902A1 (en) | 2015-03-24 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers |
| WO2016150903A1 (en) | 2015-03-24 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas |
| TW201710251A (zh) * | 2015-05-27 | 2017-03-16 | 諾福根有限公司 | 作為抗癌藥劑之經官能化及取代之吲哚 |
| JP6970081B2 (ja) * | 2015-07-16 | 2021-11-24 | 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 | アニリンピリミジン誘導体及びその使用 |
| RU2018106483A (ru) | 2015-07-24 | 2019-08-26 | Блюпринт Медсинс Корпорейшн | Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr |
| EP3356373B1 (de) | 2015-09-29 | 2020-02-19 | Bayer Pharma Aktiengesellschaft | Neuartige makrocyclische sulfondiiminverbindungen |
| CN108368129B (zh) | 2015-10-08 | 2021-08-17 | 拜耳医药股份有限公司 | 改性大环化合物 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| WO2017125530A1 (en) | 2016-01-22 | 2017-07-27 | Janssen Pharmaceutica Nv | New substituted cyanoindoline derivatives as nik inhibitors |
| CN109641882B (zh) * | 2016-06-30 | 2022-10-28 | 杨森制药有限公司 | 作为nik抑制剂的杂芳族衍生物 |
| ES2837157T3 (es) | 2016-06-30 | 2021-06-29 | Janssen Pharmaceutica Nv | Derivados de cianoindolina como inhibidores de NIK |
| EP3518931A4 (de) | 2016-09-27 | 2020-05-13 | Vertex Pharmaceuticals Incorporated | Verfahren zur behandlung von krebs mit einer kombination aus dna-schädigenden substanzen und dna-pk-inhibitoren |
| ES2900199T3 (es) | 2017-03-28 | 2022-03-16 | Bayer Ag | Novedosos compuestos macrocíclicos inhibidores de PTEFB |
| WO2018177889A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| CN111727183B (zh) | 2018-02-13 | 2023-12-29 | 拜耳公司 | 5-氟-4-(4-氟-2-甲氧基苯基)-n-{4-[(s-甲基磺亚胺酰基)甲基]吡啶-2-基}吡啶-2-胺用于治疗弥漫性大b细胞淋巴瘤中的用途 |
| CN108864052A (zh) * | 2018-06-07 | 2018-11-23 | 福建医科大学 | 一种针对gc33-3-1抗体具有特异性识别的荧光探针的合成以及应用 |
| AU2019340402B2 (en) | 2018-08-17 | 2025-04-03 | Ptc Therapeutics, Inc. | Method for treating pancreatic cancer |
| CN109776513A (zh) * | 2019-03-18 | 2019-05-21 | 福建省医学科学研究院 | 一类4-苯基-1,3,5-三嗪-2-胺类抗肿瘤化合物及其制备方法 |
| SI3953357T1 (sl) | 2019-04-12 | 2024-08-30 | Blueprint Medicines Corporation | Pirolotriazinski derivati za zdravljenje bolezni, posredovanih s KIT in PDGFRA |
| SMT202300447T1 (it) | 2019-04-12 | 2024-01-10 | Blueprint Medicines Corp | Forme cristalline di (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-yl)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-ammina e metodi di produzione |
| CN110283130B (zh) * | 2019-07-05 | 2023-12-19 | 温州医科大学 | 一种1-(2,5-二甲氧基苯基)-3-取代脲类结肠癌抑制剂及其制备和应用 |
| KR102333854B1 (ko) * | 2019-10-24 | 2021-12-06 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 신규한 피리디닐트리아진 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 |
| CN111057021B (zh) * | 2019-12-11 | 2023-05-23 | 中国药科大学 | 均三嗪类化合物及其制备方法和用途 |
| JP7772771B2 (ja) * | 2020-07-14 | 2025-11-18 | 武漢朗来科技発展有限公司 | Ｒｏｃｋ阻害剤及びその製造方法と用途 |
| EP4263531A2 (de) * | 2020-12-16 | 2023-10-25 | IFM Due, Inc. | Verbindungen und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit sting-aktivität |
| CN120025281A (zh) * | 2025-04-22 | 2025-05-23 | 九洲药业(杭州)有限公司 | 一种n,n-二异丁基-1h-吲唑-4-胺的中间体及制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US589030A (en) * | 1897-08-31 | Path delineating | ||
| US3074943A (en) * | 1963-01-22 | Substituted tkiazines and process | ||
| US2474194A (en) * | 1941-08-30 | 1949-06-21 | American Cyanamid Co | N-heterocyclic substituted guanamines |
| CH261812A (de) * | 1946-08-16 | 1949-05-31 | Ag J R Geigy | Verfahren zur Herstellung eines substituierten 2,4-Diamino-1,3,5-triazins. |
| US3136816A (en) * | 1960-03-14 | 1964-06-09 | Sterling Drug Inc | 1-(lower alkylmercapto-chloro-phenyl) biguanides |
| GB1390235A (en) * | 1971-08-07 | 1975-04-09 | Kakenyaku Kako Kk | 2-amino-4,6substituted-s triazines and methods for their preparation |
| DE2861560D1 (en) | 1977-11-28 | 1982-03-04 | Barry Boettcher | Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes |
| HU206337B (en) | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
| US4983608A (en) * | 1989-09-05 | 1991-01-08 | Hoechst-Roussell Pharmaceuticals, Inc. | N-substituted-4-pyrimidinamines and pyrimidinediamines |
| DE4025338A1 (de) * | 1990-08-10 | 1992-02-13 | Bayer Ag | Substituierte pyridine |
| US5043317A (en) * | 1990-12-14 | 1991-08-27 | Eastman Kodak Company | Yellow dye mixture for thermal color proofing |
| GB9309573D0 (en) | 1993-05-10 | 1993-06-23 | Merck Sharp & Dohme | Therapeutic agents |
| GB9403451D0 (en) * | 1994-02-23 | 1994-04-13 | Ciba Geigy Ag | Sunscreen compositions |
| TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| CN1102144C (zh) | 1994-08-13 | 2003-02-26 | 株式会社柳韩洋行 | 新的嘧啶衍生物及其制备方法 |
| US5935966A (en) * | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| TW517055B (en) * | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
| DE19750701A1 (de) * | 1997-11-15 | 1999-05-20 | Dystar Textilfarben Gmbh & Co | Verfahren zur Umsetzung von fluorsubstituierten Heterocyclen mit Aminen in Gegenwart von Phasentransfer-Katalysatoren |
| AU2053699A (en) * | 1997-12-15 | 1999-07-05 | Peptor Ltd. | Branched building units for synthesizing cyclic peptides |
| DE69839735D1 (de) | 1997-12-15 | 2008-08-28 | Astellas Pharma Inc | Pyrimidin-5-carboxamid-derivate |
| BR9908004A (pt) | 1998-02-17 | 2001-12-18 | Tularik Inc | Composto, composição e método para prevençãoou supressão de uma infecção viral |
| NZ506679A (en) | 1998-03-27 | 2002-11-26 | Janssen Pharmaceutica Nv | HIV inhibiting pyrimidine derivatives |
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| DE69933680T2 (de) | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | Pyrimidine verbindungen |
| SK287269B6 (sk) | 1998-11-10 | 2010-05-07 | Janssen Pharmaceutica N. V. | Derivát pyrimidínu, jeho použitie, spôsob jeho prípravy a farmaceutická kompozícia, kombinácia a produkt s jeho obsahom |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| JP2002535318A (ja) * | 1999-01-22 | 2002-10-22 | アムジエン・インコーポレーテツド | キナーゼ阻害薬 |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| EP1040831A3 (de) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Verwendung von Corticotropin Releasing Factor (CRF) Antagonisten zur Prophylaxe des plötzlichen Todes |
| GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
| CO5170501A1 (es) | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| DE60006541D1 (de) | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
| JP4919566B2 (ja) | 1999-09-24 | 2012-04-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗ウイルス組成物 |
| GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1244650B1 (de) | 1999-11-29 | 2003-06-25 | Aventis Pharma S.A. | Arylaminderivate und ihre verwendung als antitelomerasemittel |
-
2000
- 2000-10-06 AT AT00972036T patent/ATE396978T1/de not_active IP Right Cessation
- 2000-10-06 DE DE60039059T patent/DE60039059D1/de not_active Expired - Lifetime
- 2000-10-06 JP JP2001528166A patent/JP2003511378A/ja not_active Withdrawn
- 2000-10-06 MX MXPA02003436A patent/MXPA02003436A/es not_active Application Discontinuation
- 2000-10-06 ES ES00972036T patent/ES2306671T3/es not_active Expired - Lifetime
- 2000-10-06 EP EP00972036A patent/EP1218360B1/de not_active Expired - Lifetime
- 2000-10-06 WO PCT/US2000/027811 patent/WO2001025220A1/en not_active Ceased
- 2000-10-06 AU AU10754/01A patent/AU770600B2/en not_active Ceased
- 2000-10-06 CA CA002386218A patent/CA2386218A1/en not_active Abandoned
-
2003
- 2003-10-31 US US10/699,518 patent/US7074789B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003511378A (ja) | 2003-03-25 |
| US7074789B2 (en) | 2006-07-11 |
| AU1075401A (en) | 2001-05-10 |
| DE60039059D1 (de) | 2008-07-10 |
| EP1218360A1 (de) | 2002-07-03 |
| CA2386218A1 (en) | 2001-04-12 |
| MXPA02003436A (es) | 2002-08-20 |
| US20040116388A1 (en) | 2004-06-17 |
| EP1218360B1 (de) | 2008-05-28 |
| AU770600B2 (en) | 2004-02-26 |
| WO2001025220A1 (en) | 2001-04-12 |
| ES2306671T3 (es) | 2008-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE396978T1 (de) | Triazin-kinase-hemmer | |
| WO2000043373A3 (en) | Kinase inhibitors | |
| CA2400447A1 (en) | Kinase inhibitors | |
| AP1498A (en) | Inhibitors of impdh enzyme. | |
| DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| DE60332604D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| NO20023831L (no) | Pyrrol substituert 2-indolinonproteinkinaseinhibitorer | |
| MXPA05012812A (es) | Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp). | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| TW200801008A (en) | Protein kinase inhibitors | |
| MX2010005950A (es) | 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa. | |
| NO20061194L (no) | Mitotiske kinesininbibitorer | |
| MXPA02005844A (es) | Inhibidores de cinasas de proteina. | |
| DE60142921D1 (de) | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren | |
| EP1631548A4 (de) | Hemmer der akt aktivität | |
| EP1737843A4 (de) | Hemmer der akt aktivität | |
| MXPA05013076A (es) | Compuestos de isoindolina-1-ona como inhibidores de cinasa. | |
| ATE554087T1 (de) | Neue kinaseinhibitoren | |
| PL406680A1 (pl) | Inhibitory kinaz tyrozynowych | |
| DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| WO2004030620A3 (en) | Novel tyrosine kinase inhibitors | |
| SG132683A1 (en) | Imidazopyrazine tyrosine kinase inhibitors | |
| TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
| EP1622616A4 (de) | Hemmer der akt aktivität | |
| TW200720268A (en) | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |